TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Nykode Therapeutics ASA
Closing information (x1000 NOK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
8,679
|
12,902
|
7,168 |
| Financial expenses |
6,182
|
4,678
|
6,464 |
| Earnings before taxes |
-45,513
|
-44,086
|
-50,983 |
| Total assets |
153,481
|
208,185
|
221,477 |
| Current assets |
117,066
|
165,675
|
211,873 |
| Current liabilities |
9,099
|
20,608
|
38,985 |
| Equity capital |
136,214
|
171,259
|
157,018 |
| - share capital |
367
|
367
|
338 |
| Employees (average) | 139 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
88.7%
|
82.3%
|
70.9% |
| Turnover per employee | 62 | ||
| Profit as a percentage of turnover |
-524.4%
|
-341.7%
|
-711.3% |
| Return on assets (ROA) |
-25.6%
|
-18.9%
|
-20.1% |
| Current ratio |
1286.6%
|
803.9%
|
543.5% |
| Return on equity (ROE) |
-33.4%
|
-25.7%
|
-32.5% |
| Change turnover |
-4,223
|
5,734
|
-26,795 |
| Change turnover % |
-33%
|
80%
|
-79% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.